Insight
The Medical Layer Investors Skip When Funding Longevity and Performance Programs
Why Most Longevity Interventions Don't Survive Past Week 6
Evidence on the Ingredient vs. Evidence on the Product: What Longevity Investors Must Ask
Why "GLP-1 Customer" Is Not a Single Segment for Longevity Businesses
Build, Convert, or Ring Fence: The First Decision in a Hospital Longevity Clinic
Building a Longevity Business That Pays for Itself: The Multi-Customer Model
The Hidden Economics of Athlete Longevity: What Sports Clubs Are Missing
Why Diagnostics Alone Don't Make a Longevity Business
